Stock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth

Stock Track

Aug 29, 2025

Shares of Everest Medicines plummeted 5.05% in early trading after the company released its interim results for the first half of 2025. Despite reporting a 48% year-over-year increase in revenue to RMB446.1 million, investors appeared disappointed by supply constraints that impacted sales of the company's key product NEFECON in the first half.

While Everest Medicines saw its net loss narrow significantly to RMB249.8 million from RMB632.4 million a year earlier, the company noted that NEFECON revenue was "artificially low" in H1 due to production delays. However, management expressed confidence in full-year NEFECON sales reaching RMB1.2-1.4 billion following the resolution of supply issues in August.

The sharp stock decline suggests the market had higher expectations for Everest's H1 performance or is taking a cautious view on the company's ability to meet its ambitious full-year targets. With a solid cash position of RMB1.59 billion, investors will be closely watching whether Everest can accelerate NEFECON sales in the second half to achieve its guidance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1174371831"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174371831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174371831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174371831","market":"sg","top_or_hot":-1,"title":"Stock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth","media":"Stock Track","content":"<p>Shares of Everest Medicines plummeted 5.05% in early trading after the company released its interim results for the first half of 2025. Despite reporting a 48% year-over-year increase in revenue to RMB446.1 million, investors appeared disappointed by supply constraints that impacted sales of the company's key product NEFECON in the first half.</p>\n\n<p>While Everest Medicines saw its net loss narrow significantly to RMB249.8 million from RMB632.4 million a year earlier, the company noted that NEFECON revenue was \"artificially low\" in H1 due to production delays. However, management expressed confidence in full-year NEFECON sales reaching RMB1.2-1.4 billion following the resolution of supply issues in August.</p>\n\n<p>The sharp stock decline suggests the market had higher expectations for Everest's H1 performance or is taking a cautious view on the company's ability to meet its ambitious full-year targets. With a solid cash position of RMB1.59 billion, investors will be closely watching whether Everest can accelerate NEFECON sales in the second half to achieve its guidance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-29 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Everest Medicines plummeted 5.05% in early trading after the company released its interim results for the first half of 2025. Despite reporting a 48% year-over-year increase in revenue to RMB446.1 million, investors appeared disappointed by supply constraints that impacted sales of the company's key product NEFECON in the first half.</p>\n\n<p>While Everest Medicines saw its net loss narrow significantly to RMB249.8 million from RMB632.4 million a year earlier, the company noted that NEFECON revenue was \"artificially low\" in H1 due to production delays. However, management expressed confidence in full-year NEFECON sales reaching RMB1.2-1.4 billion following the resolution of supply issues in August.</p>\n\n<p>The sharp stock decline suggests the market had higher expectations for Everest's H1 performance or is taking a cautious view on the company's ability to meet its ambitious full-year targets. With a solid cash position of RMB1.59 billion, investors will be closely watching whether Everest can accelerate NEFECON sales in the second half to achieve its guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1174371831","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174371831","pubTimestamp":1756431498,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Everest Medicines plummeted 5.05% in early trading after the company released its interim results for the first half of 2025. Despite reporting a 48% year-over-year increase in revenue to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"个股追踪|尽管营收增长，Everest Medicines H1业绩公布后仍暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"Shares of Everest Medicines plummeted 5.05% in early trading after the company released its interim results for the first half of 2025. Despite reporting a 48% year-over-year increase in revenue to RMB446.1 million, investors appeared disappointed by supply constraints that impacted sales of the company's key product NEFECON in the first half.\nWhile Everest Medicines saw its net loss narrow significantly to RMB249.8 million from RMB632.4 million a year earlier, the company noted that NEFECON revenue was \"artificially low\" in H1 due to production delays. However, management expressed confidence in full-year NEFECON sales reaching RMB1.2-1.4 billion following the resolution of supply issues in August.\nThe sharp stock decline suggests the market had higher expectations for Everest's H1 performance or is taking a cautious view on the company's ability to meet its ambitious full-year targets. With a solid cash position of RMB1.59 billion, investors will be closely watching whether Everest can accelerate NEFECON sales in the second half to achieve its guidance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}